Oct. 26 at 1:08 AM
$BHC $BLCO RBC had this interesting comment on potential sale timing..
RBC Capital has reiterated its Market Perform rating and US
$10 price target on Bausch Health Companies (BHC.NaE) ahead of its third-quarter results.
Analyst Douglas Miehm estimates third quarter revenue of US
$2.65 billion (vs. cons. US
$2.62 billion).
Key areas of focus include updates on the ongoing Xifaxan patent litigation and potential policy-related headwinds, Miehm notes. "Additionally, we will look for commentary on management's strategic vision for the BLCO asset. In our view, should a sale of the asset materialize, it would most likely occur in the 2026/2027 time frame."